JAK2 and glioblastoma: We have previously demonstrated that inhibiting the JAK2/STAT3 pathway in GBM BTICs using the JAK2 inhibitors, WP1066 and Cucurbitacin-I, led to on-target inhibition of downstream STAT3 signaling, decreased the viability of molecularly heterogeneous BTICs in vitro, and improved survival in an orthotopic BTIC xenograft mouse model [17].